Mabel Mascarenhas, Pinal Chaudhari, Lakshmi Sruthi Mallela, Sanhita Roy, Sumit Birangal, Vivek Ghate, Ananthamurthy Koteshwara, Jesil Aranjani, Arun K. Kodoth, Shaila A. Lewis
{"title":"Natamycin Cyclodextrin Supramolecular Complex Loaded Dissolvable Lenses for the Effective Management of Fungal Keratitis","authors":"Mabel Mascarenhas, Pinal Chaudhari, Lakshmi Sruthi Mallela, Sanhita Roy, Sumit Birangal, Vivek Ghate, Ananthamurthy Koteshwara, Jesil Aranjani, Arun K. Kodoth, Shaila A. Lewis","doi":"10.1007/s12247-025-10137-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The only commercially available topical treatment for Fungal Keratitis (FK) that has been approved by the United States Food and Drug Administration (US FDA) is the 5% w/v suspension of Natamycin (Nat). Its very poor water solubility (~ 30–50 mg/L), which limits its absorption and therapeutic efficacy, is the main disadvantage that limits its clinical use. A lengthy dose schedule, low ocular retention, and a < 5% ocular bioavailability are the main disadvantages of topical ocular administration therapy.</p><h3>Methods</h3><p>The present study aimed to increase the aqueous solubility of natamycin and furthermore, increase its retention at the ocular surface by incorporating it into a dissolvable lens. Novel ophthalmic formulations were formulated with Natamycin-Sulfobutylether-β-cyclodextrin (Nat/SBE-β-CD) binary complex and ternary complexes with Polyvinyl alcohol or Poloxamer 407 (Nat/SBE-β-CD/PVA and Nat/SBE-β-CD/P407, respectively). In silico molecular modelling and wet lab experiments were performed to confirm the stability and complex formation. Furthermore, the complexes were incorporated into marketed and dissolvable contact lenses (CLs) and evaluated for in vitro antifungal studies and in vivo drug distribution to investigate their therapeutic efficacy and increased precorneal retention and permeation.</p><h3>Results</h3><p>The binary complex improved the Nat solubility up to ~ 80 fold, whereas the ternary complexes enhanced the drug solubility by ~ 107 fold and ~ 98 fold as compared to the pure drug. Cytocompatibility studies confirmed the safety and non-irritancy of the optimized formulations. The dissolvable CLs demonstrated greater drug loading, higher ex vivo transcorneal permeation, and antifungal efficacy than the soaked marketed CLs, which showed a sustained in vitro drug release. The binary dissolvable CLs showed higher in vivo corneal drug concentrations than the other CLs.</p><h3>Conclusion</h3><p>This study demonstrates the potential of CL-loaded inclusion complexes as alternatives to the currently approved suspension therapy for treating FK.</p><h3>Graphical Abstract</h3><p>Contact lens loaded Inclusion Complexes of Natamycin: A Potential Alternative to Conventional Suspension Therapy for Fungal Keratitis</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10137-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
The only commercially available topical treatment for Fungal Keratitis (FK) that has been approved by the United States Food and Drug Administration (US FDA) is the 5% w/v suspension of Natamycin (Nat). Its very poor water solubility (~ 30–50 mg/L), which limits its absorption and therapeutic efficacy, is the main disadvantage that limits its clinical use. A lengthy dose schedule, low ocular retention, and a < 5% ocular bioavailability are the main disadvantages of topical ocular administration therapy.
Methods
The present study aimed to increase the aqueous solubility of natamycin and furthermore, increase its retention at the ocular surface by incorporating it into a dissolvable lens. Novel ophthalmic formulations were formulated with Natamycin-Sulfobutylether-β-cyclodextrin (Nat/SBE-β-CD) binary complex and ternary complexes with Polyvinyl alcohol or Poloxamer 407 (Nat/SBE-β-CD/PVA and Nat/SBE-β-CD/P407, respectively). In silico molecular modelling and wet lab experiments were performed to confirm the stability and complex formation. Furthermore, the complexes were incorporated into marketed and dissolvable contact lenses (CLs) and evaluated for in vitro antifungal studies and in vivo drug distribution to investigate their therapeutic efficacy and increased precorneal retention and permeation.
Results
The binary complex improved the Nat solubility up to ~ 80 fold, whereas the ternary complexes enhanced the drug solubility by ~ 107 fold and ~ 98 fold as compared to the pure drug. Cytocompatibility studies confirmed the safety and non-irritancy of the optimized formulations. The dissolvable CLs demonstrated greater drug loading, higher ex vivo transcorneal permeation, and antifungal efficacy than the soaked marketed CLs, which showed a sustained in vitro drug release. The binary dissolvable CLs showed higher in vivo corneal drug concentrations than the other CLs.
Conclusion
This study demonstrates the potential of CL-loaded inclusion complexes as alternatives to the currently approved suspension therapy for treating FK.
Graphical Abstract
Contact lens loaded Inclusion Complexes of Natamycin: A Potential Alternative to Conventional Suspension Therapy for Fungal Keratitis
期刊介绍:
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.